NEWS
Tags: 

CLC Bio to develop integral analysis platform for epigenetics

CLC Bio has announced its participation in the European FP7 project, STATegra, and will receive $1.3 million out of the total $7.8M budget.

STATegra aims to develop a user-friendly integral analysis platform for different omics data that is capable of providing a more efficient use of genomics technologies. As a first, this project will generate and integrate data obtained in proteomic, metabolomic and epigenomic experiments.

'One of the big challenges today is going past the raw sequence data and getting to grips with the complexity of epigenetic processes – how, when and why are certain genes switched off or expressed?' said senior bioinformatics scientist at CLC bio, Dr Michael Lappe.

He continues: 'By working together with leading experimental researchers and using our in-house competences in world-class software engineering, we aim to leverage a framework which makes this extremely complex network biology understandable. Ultimately our tools will facilitate the translation of massive amounts of data into useful insights that can be applied in clinical settings.'

Twitter icon
Google icon
Del.icio.us icon
Digg icon
LinkedIn icon
Reddit icon
e-mail icon
Feature

Gemma Church finds out how astronomers are using simulations to investigate the extremities of our universe

Feature

Turning data into scientific insight is not a straightforward matter, writes Sophia Ktori

Feature

The Leibniz Supercomputing Centre (LRZ) is driving the development of new energy-efficient practices for HPC, as Robert Roe discovers

Feature

William Payne investigates the growing trend of using modular HPC, built on industry standard hardware and software, to support users across a range of both existing and emerging application areas

Feature

Robert Roe looks at developments in crash testing simulation – including larger, more intricate simulations, the use of optimisation software, and the development of new methodologies through collaboration between ISVs, commercial companies, and research organisations